Gainers

• CytoMed Therapeutics (NASDAQ:GDTC) shares increased by 27.1% to $1.08 during Thursday's pre-market session. The market value of their outstanding shares is at $9.9 million.
• Anbio Biotechnology (NASDAQ:NNNN) stock increased by 18.15% to $27.21. The market value of their outstanding shares is at $1.0 billion.
• ALX Oncology Holdings (NASDAQ:ALXO) shares moved upwards by 16.41% to $2.34. The company's market cap stands at $263.7 million.
• Nexalin Technology (NASDAQ:NXL) stock moved upwards by 16.19% to $0.66. The market value of their outstanding shares is at $10.5 million.
• Can Fite Biopharma (AMEX:CANF) shares moved upwards by 15.34% to $4.66. The company's market cap stands at $5.2 million.
• Align Technology (NASDAQ:ALGN) shares moved upwards by 10.43% to $178.13. The company's market cap stands at $11.6 billion. As per the press release, Q4 earnings came out yesterday.

Losers

• ENDRA Life Sciences (NASDAQ:NDRA) shares decreased by 11.8% to $3.43 during Thursday's pre-market session. The market value of their outstanding shares is at $4.5 million.
• Omnicell (NASDAQ:OMCL) shares decreased by 11.12% to $41.5. The company's market cap stands at $2.1 billion. As per the press release, Q4 earnings came out today.
• Agape ATP (NASDAQ:ATPC) shares declined by 9.05% to $0.08. The market value of their outstanding shares is at $4.2 million.
• TuHURA Biosciences (NASDAQ:HURA) shares fell 8.93% to $0.42. The market value of their outstanding shares is at $26.1 million.
• Accuray (NASDAQ:ARAY) shares fell 7.82% to $0.7. The market value of their outstanding shares is at $85.7 million. As per the press release, Q2 earnings came out yesterday.
• Tempest Therapeutics (NASDAQ:TPST) shares decreased by 7.57% to $2.2. The company's market cap stands at $11.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.